SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Aventus

Aventus ($AVT.X) is trending amid community excitement, with many highlighting its low market cap and potential for significant gains, especially as it's listed on Coinbase. Discussions revolve around breaking resistance levels and the possibility of a new exchange listing acting as a catalyst. Some users also point to its underlying technology and partnerships as reasons for its potential.

Brewski

$BREWSKI.X is trending as users celebrate 'American spirit' and brotherhood, frequently pairing it with meme-related coins. The community is highlighting potential whale activity and positioning it as the 'next great American runner'. Conversations also suggest a potential connection to current political trends.

Ankr is a Web3 decentralized infrastructure provider that helps developers, dapps, and stakers easily interact with multiple blockchains. It allows you to create DApps using API and RPC, staking on Ankr Earn, and use customized blockchain solutions for businesses.

Ankr Network

Ankr Network ($ANKR.X) is trending amid mixed sentiment, with some community members highlighting its infrastructure role and potential for developers, while others express frustration with its price performance and call it a "scam token." Discussions also revolve around the upcoming Neura L1 blockchain and its potential impact on the token's utility and value, with some hoping for a coin burn mechanism to drive demand.

Lucid Group, Inc. manufactures electric vehicles. It designs, develops, and builds energy storage systems for electric vehicles and supplies automakers with the battery pack system needed to power hybrid, plug-in, and electric vehicles. The company was founded in December 2007 and is headquartered in Newark, CA.

Lucid Group Inc

Lucid Group is trending due to concerns about production timelines for their Gravity SUV and the overall company's profitability, reflected in negative sentiment from some investors. Despite a recent commercial spot during an NFL game and news of accelerated Gravity SUV production, some community members express skepticism about Lucid's financial future and the effectiveness of the reverse stock split. Discussions also involve potential future funding from Saudi PIF and comparisons to other EV manufacturers like Tesla and Rivian.

Pump.fun

$PUMP.X is trending as traders discuss its potential, recent website updates, and community takeover of creator rewards, driving bullish sentiment. Conversations revolve around potential breakout points, with community members calling for it to reach penny status. The coin is associated with the meme coin launchpad Pump.fun on the Solana network.

Keeta is a high-performance layer-1 blockchain designed to unify transactions across different blockchains and fiat payment systems, eliminating the need for costly intermediaries, reducing fees, and enabling near-instant settlements. With 400-millisecond transaction finality and the ability to process 10 million transactions per second, Keeta sets a new industry benchmark for speed and scalability.  Founded in 2022 and backed by Eric Schmidt, the former CEO of Google, Keeta has been engineered to meet the stringent regulatory and operational requirements of financial institutions. Its advanced on-chain compliance protocols, including KYC and AML, ensure security and regulatory adherence. Keeta’s architecture natively supports asset tokenization and digital identity, making it an ideal platform for stablecoins and real-world asset transfers.  By facilitating cross-chain transactions and interoperability with existing payment systems, Keeta bridges the gap between cryptocurrencies and fiat, enabling a secure, efficient, and compliant global financial ecosystem.

Keeta

Keeta ($KTA.X) is trending amid anticipation for its mainnet launch and excitement surrounding its potential to revolutionize traditional finance. Community members highlight Keeta's anchor technology and partnerships as key drivers for unifying blockchains. The recent listing on exchanges like Coinbase is also fueling positive sentiment, with some suggesting it will replace other blockchains.

Navitas Semiconductor Corp. engages in the development of ultra-efficient gallium nitride (GaN) semiconductors. Its GaN power ICs integrate GaN power with drive, control and protection to enable charging, power density, and energy savings for mobile, consumer, enterprise, eMobility and new energy markets. The company was founded by Daniel Kinzer, Nick Fichtenbaum, Gene Sheridan, and Jason Zhang on August 12, 2020 and is headquartered in Torrance, CA.

Navitas Semiconductor Corp

Navitas Semiconductor ($NVTS) is trending amid community discussions around a potential breakout and anticipation for news related to its partnership with Nvidia ($NVDA). Some traders speculate about a possible acquisition, while others are focused on insider trading activity and the impact of the new CEO, Chris Allexandre, on the company's future direction in AI data centers.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

CRMD is trending due to recent financial guidance updates and the completed acquisition of Melinta Therapeutics, with the community actively discussing the potential impacts of the acquisition and future revenue projections. Some are concerned about potential executive stock sales, while others are optimistic about the company's growth and the potential for a short squeeze. Discussions also revolve around DefenCath's adoption rates and potential CMS policy changes.

Trump For President

The TRUMP.X cryptocurrency is trending amid discussions about its potential connection to Donald Trump's political activities and the launch of new related tokens. The community is actively debating the coin's utility, speculating on its future value, and expressing concerns about market manipulation. Some users are also referencing Trump's recent activities and their potential impact on the coin's performance.

Newmont Corp. engages in the exploration and acquisition of gold properties, containing copper, silver, lead, zinc or other metals. It operates through the following geographical segments: Canada, Mexico, Suriname, Argentina, Peru, Australia, Papua New Guinea, Ghana, and U.S. The company was founded by William Boyce Thompson on May 2, 1921 and is headquartered in Denver, CO.

Newmont Corp

Newmont is trending as investors discuss its aggressive capital allocation strategy amid strong gold prices, including a massive buyback program and significant shareholder returns. Community members are weighing the impact of these factors, alongside potential cost-cutting measures and unusual options activity, on the company's future performance and stock price, with some highlighting its potential for further gains.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Does Septerna, Inc. (SEPN) Have the Potential to Rally 151.27% as Wall Street Analysts Expect?

ETFs to Capitalize on the Novo Nordisk-Septerna Deal

Septerna Stock Surges on Oral Obesity Drug Deal With Novo Nordisk

Danish drug maker Novo Nordisk (NVO) on Tuesday announced an exclusive global collaboration and license agreement with U.S.-based Septerna, Inc. (SEPN) to discover, develop, and commercialise oral small-molecule medicines for obesity, type 2 diabetes, and other cardiometabolic diseases.The company <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=916006">said</a> the deal could be worth up to $2.2 billion. This includes more than $200 million in upfront and near-term milestone payments to Septerna and additional research, development, and commercial milestone payments.The California-based company is also eligible to receive tiered royalties on global net sales of marketed products.Novo Nordisk will cover all research and development expenses for partnered programs under the collaboration.The agreement is expected to close in the second quarter of 2025.The companies will initially commence four development programmes for potential small-molecule therapies directed at select G-protein-coupled receptor (GPCR) targets. GPCRs are a large and diverse family of cell membrane proteins involved in cellular communication.Septerna CEO Jeffrey Finer said that the collaboration provides an opportunity to create multiple oral medicines and provides the company with the operational flexibility and resources to advance its portfolio of other GPCR-targeted programmes.On Stocktwits, retail sentiment around Novo Nordisk fell from ‘bullish’ to ‘bearish’ territory over the past 24 hours while message volume dropped from ‘extremely high’ to ‘high’ levels.<figure class="image"><img style="aspect-ratio:629/64;" src="https://news.stocktwits-cdn.com/Screenshot_2025_05_14_at_8_28_57_AM_png_13db4d5cfd.webp" alt="Screenshot 2025-05-14 at 8.28.57 AM.png" width="629" height="64"><figcaption>NVO's Sentiment Meter and Message Volume as of 8:30 a.m. ET on May 14, 2025 | Source: Stocktwits</figcaption></figure> Meanwhile, retail sentiment on Septerna jumped from ‘bearish’ to ‘extremely bullish’ territory while message volume jumped from ‘normal’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:628/62;" src="https://news.stocktwits-cdn.com/Screenshot_2025_05_14_at_8_31_56_AM_png_a149898af9.webp" alt="Screenshot 2025-05-14 at 8.31.56 AM.png" width="628" height="62"><figcaption>SEPN's Sentiment Meter and Message Volume as of 8:35 a.m. ET on May 14, 2025 | Source: Stocktwits</figcaption></figure> A Stocktwits user expressed concerns about the new agreement, opining that Septerna’s pipeline is in the “early stage.”<stembedurl>https://stocktwits.com/NEVER_SAY_TRANSITORY/message/614571231</stembedurl>However, another investor expressed optimism on the stock if it breaks the $12.40 mark.<stembedurl>https://stocktwits.com/Trad3Slinger/message/614572114</stembedurl><a href="https://stocktwits.com/symbol/SEPN">SEPN stock</a> is up by about 70% in premarket trading on Wednesday.The stock is down by 68% this year and nearly 69% over the past 12 months.<a href="https://stocktwits.com/symbol/NVO">NVO stock</a>, meanwhile, is trading nearly 3% higher in pre-market.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/nvidia-backed-databricks-acquires-database-startup-neon/chiqpslRbNL">Nvidia, Microsoft-Backed Databricks Bets Big On AI Agents With $1B Neon Takeover: Retail Turns Extremely Bullish</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a Novo Nordisk logo is displayed on a smartphone with stock market percentages in the background. (Photo Illustration by Omar Marques/SOPA Images/LightRocket via Getty Images)

Novo Nordisk Inks $2.2B Deal With Septerna: Retail’s Thrilled

Septerna CEO Jeffrey Finer said that the collaboration allows the company to create multiple oral medicines and provides the operational flexibility and resources to advance its portfolio of other GPCR-targeted programmes.

Equity

Septerna Poised For Biopharma Breakthrough: Analysts Cite GPCR Innovation And 2025 Milestones

Analysts initiated coverage on Septerna, Inc. with Overweight ratings and price targets of $50 and $38. SEPN's innovative platform and potential pipeline make it a promising biopharma player.
read...

Septerna, Inc. is a clinical-stage biotechnology company, which engages in pioneering a new era of G protein-coupled receptor oral small molecule drug discovery powered by proprietary Native Complex PlatformTM. Its pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. The company was founded by Robert Joseph Lefkowitz, Arthur Christopoulos, Patrick Sexton, and Jeffrey T. Finer in December 2019 and is headquartered in South San Francisco, CA.

Current Price	$14.43
Prev Close	$14.12
Open	$14.35
Dividend Yield	0.00%
50-Day Moving Average	$11.99
Beta	1.43
Avg. Volume	230,385.29
PE Ratio	-6.56

52-Week High	$28.99
52-Week Low	$4.17
Market Capitalization	$629.54M
EPS (Annual)	-$1.62
Price to Book	1.67
Revenue Per Employee	$14,333.33
Enterprise Value/EBITDA	N/A

SEPN
Septerna Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest SEPN News

SEPN Septerna Inc.